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Robin J. Leatherbarrow‡‡a and Edward W. Tate*a
N-Myristoyltransferase (NMT) is a potential drug target in Leishmania parasites. Scaffold-hopping from pub-
lished inhibitors yielded the serendipitous discovery of a chemotype selective for Leishmania donovani
NMT; development led to high affinity inhibitors with excellent ligand efficiency. The binding mode was
characterised by crystallography and provides a structural rationale for selectivity.
Introduction
Leishmaniases are a spectrum of neglected tropical diseases
resulting from the infection with parasites of the genus
Leishmania spp., transmitted by the bite of the female
Phlebotomine sandfly to the human host. The disease mani-
fests in one of three forms (cutaneous, mucocutaneous and
visceral)1 and is responsible for an estimated 60 000 deaths
and in excess of 500 000 new cases per annum.2 The majority
of fatalities stem from visceral leishmaniasis, which is pre-
dominately the result of infection by Leishmania donovani
(Ld).3 As with many neglected diseases, the leishmaniases are
most prevalent in developing and newly industrialized
nations4 and although treatments exist, the majority suffer
from significant levels of resistance and toxicity.5 Leishmania
spp. infections remain challenging to treat chemotherapeutically;
many currently marketed drugs display EC50 values in the low
μM range in in vitro models,5,6 orders of magnitude higher
than the potency typically targeted in an anti-infective drug
discovery project. In order to combat the continued evolution
of the parasite in developing resistance, new chemotherapies
functioning by novel mechanisms of action are essential.
N-Myristoyltransferase (NMT) is a ubiquitous eukaryotic
enzyme responsible for the attachment of the long chain fatty
acid myristate to the N-terminus of substrate proteins. This
modification is crucial in many biological processes,7–10 and
NMT has been implicated as a highly promising drug target
in fungal11 and parasitic infections,12–14 as recently demon-
strated in human malaria parasites.15 In the specific context
of leishmaniasis, NMT has been validated genetically in
Leishmania major (Lm),16 and through chemical proteomic
approaches in Ld,17 and selective small molecule inhibitors of
this drug target are highly desirable.
Results and discussion
We have previously reported the discovery of LdNMT inhibi-
tors by high-throughput screening,18–21 as well as the discov-
ery of Plasmodium falciparum (Pf) and Plasmodium vivax (Pv)
NMT inhibitors by both high-throughput screening22 and
piggy-back/lead-hopping approaches.23–25 Throughout this
work, all compounds were routinely screened against all
three parasitic enzymes (LdNMT, PfNMT and PvNMT) and
Homo sapiens (Hs) NMT, where selectivity over the human
orthologue was desired to minimise any potential toxicity
from modulating endogenous myristoylation. 2,3-Substituted
benzo[b]thiophenes were discovered as ligand-efficient inhib-
itors of PfNMT, which incidentally displayed selectivity over
LdNMT (Fig. 1).25
During studies to reduce the molecular weight and lipo-
philicity of 1 in the further development of the series against
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plasmodial NMT, the bicyclic benzo[b]thiophene of 1 was
truncated to a monocyclic scaffold (Scheme 1).
The affinity spectrum of compound 5 is strikingly distinct
from that observed with benzo[b]thiophene 1 (Table 1). The
activity against human and both Plasmodium enzymes drops
by almost two orders of magnitude, whereas the affinity
against LdNMT improves 8-fold, a significant improvement
when considering the loss of 4 heavy atoms and attendant
reduction in lipophilicity.
Based on this affinity profile and structural analysis of the
binding mode of 1 in PvNMT,25 it became clear that the
monocyclic thiophene scaffold was unlikely to be a suitable
chemotype for Plasmodium NMT inhibitors. However, 5 dis-
plays a very promising profile as a LdNMT inhibitor with
excellent selectivity and LE, as well as sub-μM enzyme affin-
ity. 5 was selected for further development, with the aim of
discovering a new lead series for LdNMT inhibitors.
Although heterocycles are often preferred as bioisosteres
for a phenyl ring, thiophene has been associated with cyto-
chrome P450 inhibition and generally low “developability”
during optimisation.26 Replacing the thiophene with a phenyl
was deemed preferable, and provided a cost-effective syn-
thetic route and versatility to variations around the scaffold.
Pleasingly, this modification from thiophene to phenyl
produced a further 3-fold improvement in enzyme affinity,
whilst maintaining physicochemical properties and selectivity
(Table 1). Interestingly, compounds with a phenyl scaffold
proved amenable for development into high affinity Plasmo-
dium NMT inhibitors – this work shall be reported elsewhere.27
Compound 6 has a promising affinity profile, but further
development of the series would require removal of the
Fig. 1 NMT affinity profile for 2,3-substituted benzo[b]thiophene 1:
aEnzyme apparent Ki values are calculated from the IC50 values using
the Cheng–Prusoff equation (see ESI†) to enable cross-comparisons.
IC50 values were the mean of two or more independent
determinations. Standard deviation is within 20% of reported IC50.
bHsNMT affinities reported in this work refer to HsNMT1; no significant
difference in inhibition was observed between HsNMT1 and HsNMT2
isoforms.18
Scheme 1 Synthesis of truncated inhibitor 5. Reagents and conditions: (a) 1-Boc-4-piperidinol, DIAD, PPh3. THF, rt, 4 h, 94%; (b) NaOH, MeOH/
H2O, 50 °C, 2 h, 90%; (c) Ĳ3-methoxyphenyl)methanol, EDCI, HOBt, DIPEA, MeCN, rt, 18 h; (d) 10% TFA in DCM Ĳv/v), rt, 2 h, 9% over 2 steps.
Table 1 Enzyme affinity and parasitic LE for mono- and bicyclic analogues 1, 5 and 6
No. Structure clogPa
PfNMT PvNMT LdNMT HsNMT
Ki (μM)Ki (μM) LE
b Ki (μM) LE Ki (μM) LE
1 4.0 0.83 0.30 0.08 0.35 5.82 0.28 3.20
5 2.9 >100 — 6.50 0.30 0.73 0.35 >100
6 3.0 6.00 0.29 2.42 0.31 0.28 0.36 >100
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potentially labile ester moiety. We have previously reported the
successful replacement of the ester moiety with an oxadiazole
in related series;24,28 the same bioisosteric replacement was
implemented in the present series, with the aim of producing
a drug-like series for further development. The relatively
straightforward synthetic scheme (Scheme 2) enabled facile
synthesis of a variety of analogues, thereby allowing investiga-
tion of the preferred substituents on this ring system.
Moving from the ester linker in 6 to oxadiazole in 10a pro-
duced a ~4-fold improvement in enzyme affinity alongside
removal of the ester moiety. This compound displays measur-
able affinity against HsNMT but possesses selectivity of 20-
fold in favour of the parasite enzyme, constituting a highly
promising scaffold from which to investigate substituent
effects on the phenyl ring (Table 2).
Comparison of 10c, 10d and 10i shows the effect of scan-
ning a methyl substituent around the 3-, 4- and 5-positions
of the scaffold. In all cases this variation is less active than
the unsubstituted parent 10a, although among these three
analogues the 5-substituted 10i displays the highest affinity.
Scheme 2 Synthesis of oxadiazole derivatives 10a–k. Reagents: (a) BnBr, K2CO3, DMF, rt, 2 h, 72–89%; (b) DIAD, PPh3, N-Boc-4-OH piperidine,
THF, rt, 4 h; (c) NaOH, MeOH/H2O, 50 °C, 2 h, 80–95% over two steps; (d) NH2OH, EtOH, 80 °C, 6 h, 98%; (e) i). EDCI, HOBt, 9, DIPEA, CH3CN, rt,
4 h; ii). 0.5 N NaOH, rt, 0.5 h; (f) 10% TFA in DCM, rt, 2 h, 20–60% over 2 steps.












10ae H 3.4 0.06 0.37 1.24 >30 —
10b 3-OMe 3.2 4.02 0.26 7.23 — —
10c 3-Me 3.9 1.43 0.29 7.44 — —
10d 4-Me 3.9 5.18 0.26 4.64 — —
10ee 4-OMe 3.2 3.04 0.26 0.86 — —
10fe 4-Cl 4.0 0.36 0.32 0.45 — —
10ge 4-F 3.5 0.03 0.37 0.59 10.2 29.5
10h 4-Br 4.2 0.68 0.30 0.26 — —
10i 5-Me 3.9 0.24 0.32 0.76 — —
10j 5-Cl 4.0 0.02 0.38 0.07 6.7 18.0








13 1.8 0.01 0.39 0.02 >50 >90
a clogP values calculated with ChemAxon. b LE = ĳ−logĲKi)] × 1.374/Ĳno. of heavy atoms). c Ex vivo L. donovani amastigotes.19 d LD50 is an
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This pattern repeats when comparing the methoxy-
substituted 10b, 10e and 10k, indicating that the 5-position
is preferred for substitution. 5-OMe (10k) provides improved
potency over 5-Me (10i), and this trend continues on moving
to the 5-Cl substituent, identifying 10j as a high affinity
LdNMT inhibitor with a Ki of 0.02 μM.
The binding mode of 10j to Leishmania major NMT (98%
sequence identity to LdNMT with closely superimposable
ligand binding sites)14,29 was confirmed by determination of
the crystal structure of the ternary complex of LmNMT,
myrisotyl-CoA and 10j (PDB ID: 5a27). The inhibitor binds in
the expected site adjacent to the enzyme's C-terminal carbox-
ylate to which its piperidine forms an ion pairing interaction.
This and other key interactions are conserved in a related
series in PvNMT.24 Surprisingly, in addition to the observed
interactions between the protein and the ligand, the crystal
structure revealed a ring-opened derivative of the 1,2,4-
oxadiazole, rather than the desired heterocycle (see Fig. S1
and S2†). However, proton NMR spectroscopy and high reso-
lution mass spectrometry confirmed that the desired oxa-
diazole as the synthetic product, furthermore no degradation
of 10j was observed when this molecule was incubated at
37 °C over a wide pH range (pH 1–10, data not shown) over a
period of 24 hours. This ‘ring opening’ phenomenon has
been observed in related compounds within the program,27
although to our knowledge, it has not been reported else-
where. The origin of the ring-opened species observed in the
crystals remains unclear, and further investigation is under-
way to determine the cause of this discrepancy (such as
potential radiation damage). As characterisation of the com-
pounds was consistent with the proposed oxadiazoles, the
development of the series was continued.
A selection of compounds with LdNMT Ki < 0.1 μM (10a,
10g, 10j, 10k) were tested against ex vivo amastigotes, the
clinically-relevant life cycle stage of the parasite, to determine
the ability of these molecules to inhibit parasite growth.
These molecules displayed a narrow (within 3-fold) therapeu-
tic window against the macrophage host in vitro, and it was
unclear whether the observed anti-parasitic activity is a result
of NMT inhibition or non-specific toxicity. Given the rela-
tively high clog P of the tested compounds (>3.5), it was
hypothesised that reducing lipophilicity would lead to
reduced macrophage toxicity.30 We therefore elected to build
on our previous success in targeting the S319 pocket through
polar heterocyclic replacement of the 3-methoxyphenyl, with
the aim of producing a high affinity LdNMT inhibitor with
reduced lipophilicity.28
Replacing the 1,2,4-oxadiazole with the more polar
1,3,4-regioisomer31 and utilising a 1,3,5-trimethylpyrazole
motif to replace the hydrophobic methoxyphenyl moiety
rendered compound 13 (Scheme 3). Encouragingly, 13 is
roughly equipotent to 10j yet is predicted to be two
orders of magnitude less lipophilic, resulting in a highly
promising compound. It should be noted that neither 10j
nor 13 display significant selectivity for LdNMT over
HsNMT, highlighting a target for further development of
the series. The crystal structure of 13 bound to LmNMT
was solved (PDB ID: 5a28, Fig. 2), and this alternative
oxadiazole isomer did not display the ring-opened ana-
logue (Fig. S2†).
The basic piperidine moiety forms a polar interaction with
the carboxylate of the C-terminal residue, Leu421 and a
water-mediated interaction with Tyr92, mimicking the
N-terminus of substrate peptides (Fig. 2B). In addition, the
trimethyl pyrazole substituent forms π–π and polar interac-
tions with Phe90 and Ser330 respectively (Fig. 2C), complet-
ing the interactions observed with previous NMT inhibitors.
Of particular interest are the interactions around the inhibi-
tor core; a qualitative assessment shows the 5-chlorine
inserting into a hydrophobic pocket within the active site,
and a lack of space around the 4-position of the scaffold rein-
forces the lack of activity of the larger substitutions in this
position, in the absence of evidence for plasticity in the bind-
ing site (Fig. 2A). The rationale for the relative lack of activity
of the 3-position substituents is less clear, but may be a
result of placing a hydrophobic substituent in a water-filled
cavity, or restriction of conformation of the piperidine
moiety.
Interestingly, these conserved contacts of 1 and 13 are
achieved with remarkably distinct trajectories through the
binding site, and a comparison of the binding modes sug-
gests a rationale for the large activity difference between
PvNMT and LdNMT for 1 (Fig. 3).
The phenyl ring of the benzothiophene scaffold in 1
occupies a region of the PvNMT binding site that is not occu-
pied by 13 in LmNMT (Fig. 3A), filling a volume occupied by
two water molecules in LmNMT (Fig. 3B). Comparison of
the residues around this pocket shows some significant
Scheme 3 Synthesis of pyrazole derivative 13. Reagents and conditions: (a) 1-Boc-4-piperidinol, DIAD, PPh3. THF, rt, 4 h, 46%; (b) hydrazine
monohydrate, EtOH, reflux, 18 h, quantitative; (c) EDCI, HOBt, 2-Ĳtrimethyl-1H-pyrazol-4-yl)acetic acid,28 DIPEA, THF :DMF (4 : 1, v/v), rt, 18 h; (d)
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differences, the largest of which is Ala366 in PvNMT
substituted for Met377 in LmNMT (Fig. 3C). This shifts the
protein backbone, and likely results in a more restricted
pocket in LmNMT relative to PvNMT. The potential clash
between the LmNMT backbone and the benzothiophene core
of compound 1 provides a rationale for the reduced affinity
of this molecule for LdNMT compared to PvNMT, and also
an explanation for the activity loss in molecules carrying 4-
substituents larger than fluorine (10d–f, 10h vs. 10a, Table 2).
Compound 13 was tested against both macrophages and
Ld amastigotes. Pleasingly, 13 did not display any macro-
phage toxicity at the top concentration tested (90 μM),
reinforcing the earlier hypothesis that reducing macrophage
toxicity can be achieved by reducing lipophilicity. However,
this molecule showed no observed effect against ex vivo
amastigotes up to 50 μM.
Conclusion
In summary, commencing from a member of a previously
described series of PfNMT inhibitors, compound 5 was dis-
covered as a highly ligand efficient inhibitor of LdNMT, and
subsequent modification of the scaffold yielded the 5-chloro-
phenyl moiety as the optimum core. However, the com-
pounds showed weak activity when tested against ex vivo
amastigotes, and this appeared to correlate with macrophage
toxicity; reduction of lipophilicity led to the discovery of com-
pound 13, a high affinity LdNMT inhibitor. The binding
mode and selectivity could be rationalised by crystallography,
and comparisons to previous structures. Whilst this molecule
displayed no macrophage toxicity at all concentrations tested,
it also failed to inhibit L. donovani amastigotes; the reasons
for this lack of cellular activity remain unclear, but it is possi-
ble that this may be resolved through further optimisation of
the amine basicity and lipophilicity balance in this series.
Although NMT has great potential as a drug target in Leish-
mania parasites, these organisms are notoriously robust,6
and the physicochemical properties required for optimal
engagement of intracellular parasite drug targets in the intra-
macrophage amastigote stage remain poorly defined. Further
investigation of the influences of the physicochemical proper-
ties of this series is currently underway, alongside the introduc-
tion of new NMT inhibitor chemotypes18 with the aim of chem-
ically validating NMT as a drug target in Leishmania donovani.
Fig. 2 Crystal structure of 13 (blue) bound to LmNMT (grey). (A) The chloro-substituent is buried within a hydrophobic pocket, and appears to
have good shape complementarity with the enzyme active site. (B) In addition to the shape-complementarity of the scaffold, the compound
appears to form a similar binding mode to that previously observed. (C) The trimethylpyrazole motif forms both a hydrogen bonding interaction
with Ser330 and a hydrophobic stacking interaction with Phe90.
Fig. 3 Comparison of the crystal structure of 1 (pink) bound to PvNMT (yellow) and 13 (blue) bound to LmNMT (grey). (A) Overlay of 1 in PvNMT
and 13 in LdNMT, with the enzymes removed for clarity; the phenyl ring of the benzo[b]thiophene scaffold protrudes in the direction of potential
3- and 4-substitutions of the phenyl series. (B) The surface of the active site of LmNMT (grey) shows a constrained, water filled back pocket in the
same position as that occupied by the benzo[b]thiophene. (C) Alanine to methionine substitution in LmNMT results in a more constrained pocket























































































1766 | Med. Chem. Commun., 2015, 6, 1761–1766 This journal is © The Royal Society of Chemistry 2015
Notes
The authors declare no competing financial interest.
Acknowledgements
This work was supported by the Wellcome Trust (grant no.:
087792), the Medical Research Council (grant no.: 0900278
and U117532067) and the EU F97 project MALSIG ĲHEALTH-
F3-2009-223044). The authors are grateful to Andrew Bell and
Jennie Hutton for valuable discussions, Shirley Roberts for
crystal handling and Johan Turkenburg for X-ray data process-
ing. We also acknowledge the Diamond Light Source for syn-
chrotron facilities.
References
1 R. D. Pearson and A. de Queiroz Sousa, Clin. Infect. Dis.,
1996, 22, 1–11.
2 P. Desjeux, Comp. Immunol. Microbiol. Infect. Dis., 2004, 27,
305–318.
3 F. Chappuis, S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W.
Peeling, J. Alvar and M. Boelaert, Nat. Rev. Microbiol.,
2007, 5, 873–882.
4 WHO Leishmaniasis Programme, http://www.who.int/
leishmaniasis/en/itle, 2010.
5 S. L. Croft, S. Sundar and A. H. Fairlamb, Clin. Microbiol.
Rev., 2006, 19, 111–126.
6 P. Escobar, S. Matu, C. Marques and S. L. Croft, Acta Trop.,
2002, 81, 151–157.
7 M. D. Resh, Trends Mol. Med., 2012, 18, 206–214.
8 E. W. Tate, K. A. Kalesh, T. Lanyon-Hogg, E. M. Storck
and E. Thinon, Curr. Opin. Chem. Biol., 2014, 24C,
48–57.
9 M. H. Wright, W. P. Heal, D. J. Mann and E. W. Tate,
J. Chem. Biol., 2010, 3, 19–35.
10 E. Thinon, R. A. Serwa, M. Broncel, J. A. Brannigan, U.
Brassat, M. H. Wright, W. P. Heal, A. J. Wilkinson, D. J.
Mann and E. W. Tate, Nat. Commun., 2014, 5, 4919.
11 K. Kawasaki, M. Masubuchi, K. Morikami, S. Sogabe, T.
Aoyama, H. Ebiike, S. Niizuma, M. Hayase, T. Fujii, K.
Sakata, H. Shindoh, Y. Shiratori, Y. Aoki, T. Ohtsuka
and N. Shimma, Bioorg. Med. Chem. Lett., 2003, 13,
87–91.
12 P. Pino, S. Sebastian, E. A. Kim, E. Bush, M. Brochet, K.
Volkmann, E. Kozlowski, M. Llinás, O. Billker and D.
Soldati-Favre, Cell Host Microbe, 2012, 12, 824–834.
13 E. W. Tate, A. S. Bell, M. D. Rackham and M. H. Wright,
Parasitology, 2014, 141, 37–49.
14 J. A. Frearson, S. Brand, S. P. McElroy, L. A. T. Cleghorn, O.
Smid, L. Stojanovski, H. P. Price, M. L. S. Guther, L. S.
Torrie, D. A. Robinson, I. Hallyburton, C. P. Mpamhanga,
J. A. Brannigan, A. J. Wilkinson, M. Hodgkinson, R. Hui, W.
Qiu, O. G. Raimi, D. M. F. van Aalten, R. Brenk, I. H. Gilbert,
K. D. Read, A. H. Fairlamb, M. A. J. Ferguson, D. F. Smith
and P. G. Wyatt, Nature, 2010, 464, 728–732.
15 M. H. Wright, B. Clough, M. D. Rackham, K. Rangachari,
J. A. Brannigan, M. Grainger, D. K. Moss, A. R. Bottrill, W. P.
Heal, M. Broncel, R. A. Serwa, D. Brady, D. J. Mann, R. J.
Leatherbarrow, R. Tewari, A. J. Wilkinson, A. A. Holder and
E. W. Tate, Nat. Chem., 2014, 6, 112–121.
16 H. P. Price, M. R. Menon, C. Panethymitaki, D. Goulding,
P. G. McKean and D. F. Smith, J. Biol. Chem., 2003, 278,
7206–7214.
17 M. H. Wright, D. Paape, E. M. Storck, R. A. Serwa, D. F.
Smith and E. W. Tate, Chem. Biol., 2015, 22, 342–354.
18 A. S. Bell, J. E. Mills, G. P. Williams, J. A. Brannigan, A. J.
Wilkinson, T. Parkinson, R. J. Leatherbarrow, E. W. Tate,
A. A. Holder and D. F. Smith, PLoS Neglected Trop. Dis.,
2012, 6, e1625.
19 D. Paape, A. S. Bell, W. P. Heal, J. A. Hutton, R. J.
Leatherbarrow, E. W. Tate and D. F. Smith, PLoS Neglected
Trop. Dis., 2014, 8, e3363.
20 J. A. Hutton, V. Goncalves, J. A. Brannigan, D. Paape, M. H.
Wright, T. M. Waugh, S. M. Roberts, A. S. Bell, A. J.
Wilkinson, D. F. Smith, R. J. Leatherbarrow and E. W. Tate,
J. Med. Chem., 2014, 57, 8664–8670.
21 J. A. Brannigan, S. M. Roberts, A. S. Bell, J. A. Hutton, M. R.
Hodgkinson, E. W. Tate, R. J. Leatherbarrow, D. F. Smith
and A. J. Wilkinson, IUCrJ, 2014, 1, 250–260.
22 V. Goncalves, J. A. Brannigan, D. Whalley, K. H. Ansell, B.
Saxty, A. A. Holder, A. J. Wilkinson, E. W. Tate and R. J.
Leatherbarrow, J. Med. Chem., 2012, 55, 3578–3582.
23 T. O. Olaleye, J. A. Brannigan, S. M. Roberts, R. J.
Leatherbarrow, A. J. Wilkinson and E. W. Tate, Org. Biomol.
Chem., 2014, 12, 8132–8137.
24 Z. Yu, J. A. Brannigan, D. K. Moss, A. M. Brzozowski, A. J.
Wilkinson, A. A. Holder, E. W. Tate and R. J. Leatherbarrow,
J. Med. Chem., 2012, 55, 8879–8890.
25 M. D. Rackham, J. A. Brannigan, D. K. Moss, Z. Yu, A. J.
Wilkinson, A. A. Holder, E. W. Tate and R. J. Leatherbarrow,
J. Med. Chem., 2013, 56, 371–375.
26 T. J. Ritchie, S. J. F. Macdonald, S. Peace, S. D. Pickett and
C. N. Luscombe, Med. Chem. Commun., 2012, 3, 1062–1069.
27 Z. Yu, J. A. Brannigan, K. Rangachari, W. P. Heal, A. J.
Wilkinson, A. A. Holder, R. J. Leatherbarrow and E. W. Tate,
Med. Chem. Commun., Submitted.
28 M. D. Rackham, J. A. Brannigan, K. Rangachari, S. Meister,
A. J. Wilkinson, A. A. Holder, R. J. Leatherbarrow and E. W.
Tate, J. Med. Chem., 2014, 57, 2773–2788.
29 J. A. Brannigan, B. A. Smith, Z. Yu, A. M. Brzozowski, M. R.
Hodgkinson, A. Maroof, H. P. Price, F. Meier, R. J.
Leatherbarrow, E. W. Tate, D. F. Smith and A. J. Wilkinson,
J. Mol. Biol., 2010, 396, 985–999.
30 P. D. Leeson and B. Springthorpe, Nat. Rev. Drug Discovery,
2007, 6, 881–890.
31 J. Boström, A. Hogner, A. Llinàs, E. Wellner and A. T.
Plowright, J. Med. Chem., 2012, 55, 1817–1830.
MedChemCommConcise Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/2
0/
20
18
 9
:5
9:
46
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
